Treatment of refractory T-cell malignancies using gemcitabine
Author:
Publisher
Wiley
Subject
Hematology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-2141.2001.02743.x/fullpdf
Reference12 articles.
1. Comparison of the induction of apoptosis in human leukemia cell lines by 2′, 2′-difluorodeoxycytidine (gemcitabine) and cytosine arabinoside;Bouffard;Leukemia Research,1995
2. T-cell lymphomas: immunologic, histologic, clinical and therapeutic analysis of 63 cases;Coiffier;Journal of Clinical Oncology,1988
3. Pentostatin in T-cell malignancies: a phase II trial of the EORTC leukemia cooperative group;Ho;Annals of Oncology,1999
4. Clinical and phenotypic diversity of T-cell lymphomas;Horning;Blood,1986
5. Pathologic and clinical spectrum of post-thymic T-cell malignancy;Jaffe;Cancer Investigation,1984
Cited by 95 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma;Journal of Hematology & Oncology;2024-06-01
2. Gemcitabine and liposomal doxorubicin (GemDox) for the treatment of relapsed and refractory T-cell lymphomas;Leukemia & Lymphoma;2023-12-13
3. Continuous low‐dose gemcitabine in primary cutaneous T cell lymphoma: A retrospective study;Dermatologic Therapy;2022-04-11
4. Approved Agents in the Relapsed or Refractory Setting, Excluding Brentuximab Vedotin;The Peripheral T‐Cell Lymphomas;2021-02-19
5. The peripheral T-cell lymphomas: an unusual path to cure;The Lancet Haematology;2020-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3